Downregulation of Antigen-Presenting Cell Functions After Administration of Mitogenic Anti-CD3 Monoclonal Antibodies in Mice by Eric Muraille, Fabienne.

Slides:



Advertisements
Similar presentations
Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation by Juliette Mouriès, Gabriel Moron, Géraldine Schlecht,
Advertisements

Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
Volume 25, Issue 2, Pages (August 2006)
Peptide Immunization Indicates that CD8+ T Cells are the Dominant Effector Cells in Trinitrophenyl-Specific Contact Hypersensitivity  Stefan Martin, Michael.
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer by Ou Cao, Eric Dobrzynski,
by Yoshinobu Maeda, Pavan Reddy, Kathleen P
Thymic Selection by a Single MHC/Peptide Ligand
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
by Silke Huber, Reinhard Hoffmann, Femke Muskens, and David Voehringer
Immunologic Characterization of HIV-Specific DNA Vaccine
by Norman Nausch, Ioanna E
Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes
Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease by Tomomi Toubai, Yaping Sun, Isao Tawara, Ann Friedman,
Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.
Wei Hu, Ty Dale Troutman, Ramakrishna Edukulla, Chandrashekhar Pasare 
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
Cognate recognition of the endothelium induces HY-specific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo by Federica M. Marelli-Berg,
Ikaros is required for plasmacytoid dendritic cell differentiation
by Éric Aubin, Réal Lemieux, and Renée Bazin
Corticosteroids But Not Pimecrolimus Affect Viability, Maturation and Immune Function of Murine Epidermal Langerhans Cells  Wolfram Hoetzenecker, Josef.
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy by Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew Flies, Sarah.
by Jamie Honeychurch, Alison L. Tutt, Thomas Valerius, Ingmar A. F. M
Bifurcated Dendritic Cell Differentiation In Vitro From Murine Lineage Phenotype-Negative c-kit + Bone Marrow Hematopoietic Progenitor Cells by Yi Zhang,
Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation  Yang Wang, Dan Li, Dan Jones, Roland.
Antigen-Specific Peripheral Tolerance Induced by Topical Application of NF-κB Decoy Oligodeoxynucleotide  Iwao Isomura, Kunio Tsujimura, Akimichi Morita 
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Durbaka V.R Prasad, Sabrina Richards, Xoi Muoi Mai, Chen Dong  Immunity 
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease by Tangsheng Yi, Dongchang Zhao, Chia-Lei.
Volume 13, Issue 4, Pages (October 2000)
Volume 18, Issue 5, Pages (May 2003)
Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens  Hisaki Fujii,
Volume 11, Issue 5, Pages (November 1999)
Volume 68, Issue 3, Pages (September 2005)
Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice  Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,
Volume 13, Issue 1, Pages (January 2006)
Volume 115, Issue 4, Pages (October 1998)
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease  Isao Tawara,
Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.
Volume 116, Issue 6, Pages (June 1999)
Volume 33, Issue 4, Pages (October 2010)
CpG-Induced Myeloid CD11b+Gr-1+ Cells Efficiently Suppress T Cell–Mediated Immunoreactivity and Graft-Versus-Host Disease in a Murine Model of Allogeneic.
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
by Derek Hoi-Hang Ho, and Roger Hoi-Fung Wong
Yoav Peretz, Zheng Frank Zhou, Fawaz Halwani, Gérald J. Prud'homme 
CTLA-4 Regulates Induction of Anergy In Vivo
Volume 20, Issue 5, Pages (May 2012)
Volume 24, Issue 1, Pages (January 2016)
In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti- factor VIII Immune Responses in Hemophilia A Mice Treated With Factor.
Interleukin-21 Inhibits Dendritic Cell-Mediated T Cell Activation and Induction of Contact Hypersensitivity In Vivo  Donald C. Foster, Ralf Paus  Journal.
Volume 4, Issue 6, Pages (June 1996)
Harald Renz, MD, Chaya Brodie, PhD, Katherine Bradley, BS, Donald Y. M
PD-1 blockade enhances T-cell function.
Volume 17, Issue 5, Pages (November 2002)
Toll-Dependent Control Mechanisms of CD4 T Cell Activation
Luk Van Parijs, Alexander Ibraghimov, Abul K. Abbas  Immunity 
Mattias Svensson, Asher Maroof, Manabu Ato, Paul M. Kaye  Immunity 
Genetic Targeting of the Active Transcription Factor XBP1s to Dendritic Cells Potentiates Vaccine-induced Prophylactic and Therapeutic Antitumor Immunity 
Volume 67, Issue 6, Pages (June 2005)
Epicutaneous Sensitization with Protein Antigen Induces Th9 Cells
Volume 19, Issue 4, Pages (October 2003)
Memory CD8+ T Cells Undergo Peripheral Tolerance
Thymocyte Glucocorticoid Resistance Alters Positive Selection and Inhibits Autoimmunity and Lymphoproliferative Disease in MRL-lpr/lprMice  Eva Tolosa,
Volume 4, Issue 5, Pages (May 1996)
Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo by Holger Hackstein, Timucin Taner,
Volume 25, Issue 3, Pages (September 2006)
Presentation transcript:

Downregulation of Antigen-Presenting Cell Functions After Administration of Mitogenic Anti-CD3 Monoclonal Antibodies in Mice by Eric Muraille, Fabienne Andris, Bernard Pajak, K. Martin Wissing, Thibaut De Smedt, Fabrice Desalle, Michel Goldman, Maria-Luisa Alegre, Jacques Urbain, Muriel Moser, and Oberdan Leo Blood Volume 94(12):4347-4357 December 15, 1999 ©1999 by American Society of Hematology

Anti-CD3ɛ administration induces DC movement and maturation. Anti-CD3ɛ administration induces DC movement and maturation. (A) Immunoperoxidase staining of cryostat sections or (B) alkaline phosphatase staining of embedded serial sections of spleens from control (hamster Ig) or anti-CD3ɛ injected mice (50 μg IV), 6 and 48 hours posttreatment. Sections were stained with antibodies to CD11b, CD11c, IgD, Dec-205, and CD86 as indicated in the figure. Eric Muraille et al. Blood 1999;94:4347-4357 ©1999 by American Society of Hematology

Selective reduction of DC number after anti-CD3ɛ administration. Selective reduction of DC number after anti-CD3ɛ administration. BALB/c mice were treated on day 0 with control antibody or anti-CD3ɛ (50 μg IV) and analyzed on days 2 and 15 for I-Ed, CD45R, and CD11c expression. Pooled low-density spleen cells from 3 individuals in each group were analyzed by 2-color immunofluorescence after staining with PE-labeled anti-CD45R and FITC-labeled anti–I-Ed (A through C) or PE-labeled anti-CD45R and FITC-labeled anti-CD11c (D through F). Eric Muraille et al. Blood 1999;94:4347-4357 ©1999 by American Society of Hematology

Altered DC distribution in peripheral lymphoid and nonlymphoid organs after anti-CD3ɛ administration. Altered DC distribution in peripheral lymphoid and nonlymphoid organs after anti-CD3ɛ administration. Alkaline phosphatase staining of cryostat section of (A) hearts and (B) mesenteric lymph nodes (serial sections) from control and anti-CD3ɛ–injected mice (50 μg IV). Sections were stained with antibodies to MHC class II, CD4 and CD11c, as indicated in the figure. A higher magnification of MHC II+ cells in the heart of control mice is also shown. Eric Muraille et al. Blood 1999;94:4347-4357 ©1999 by American Society of Hematology

Defective APC function in anti-CD3ɛ–treated mice. Defective APC function in anti-CD3ɛ–treated mice. Spleen cells from control antibody-treated or anti-CD3ɛ–treated BALB/c mice (50 μg IV) were irradiated and used as accessory cells to stimulate (A and B) G10-nonadherent responding cells from CBA mice (3 × 105/well) or (C) ovalbumin-specific T-cell hybridoma mice (3 × 105/well) in the presence of 1 μg/mL of ovalbumin peptide. Proliferation (A) and IL-2 production (B and C) were assayed as described in Materials and Methods. Results are expressed as counts per minute (cpm) of [3H] TdR incorporation by responder cells (A) or IL-2–dependent cell line CTL.L (B and C). These results are representative of 3 independent experiments. Eric Muraille et al. Blood 1999;94:4347-4357 ©1999 by American Society of Hematology

APC from anti-CD3ɛ–treated mice support the growth of the Th2, but not Th1, Ag-specific clones. APC from anti-CD3ɛ–treated mice support the growth of the Th2, but not Th1, Ag-specific clones. Spleen cells from control antibody-treated or anti-CD3ɛ–treated mice (50 μg IV) were irradiated and used as accessory cells to stimulate the Th1 clones AE.7 and CLOVA 1.1 or the Th2 clones HG.4 and CLOVA 2.9 in the presence of nominal Ag. Clones were also stimulated by Ag presented by G10-depleted splenic accessory cells for the sake of comparison. Results are expressed as cpm of [3H] TdR incorporation by responder cells. These results are representative of 3 independent experiments. Eric Muraille et al. Blood 1999;94:4347-4357 ©1999 by American Society of Hematology

Downmodulation of anti-CD40–induced IL-12 secretion after anti-CD3ɛ treatment. Downmodulation of anti-CD40–induced IL-12 secretion after anti-CD3ɛ treatment. Unselected spleen cells (106cells/well) from control and anti-CD3ɛ–injected mice (48 hours posttreatment, 50 μg IV) were stimulated in vitro by an activating rat IgG2a anti-CD40 MoAb (3 μg/mL) or an equivalent amount of an isotype-matched, control antibody (clone IR418). When indicated, cultures were supplemented with a neutralizing antibody to the IL-12 subunit p40 (rat IgG2a C17.8, 5 μg/mL) or with an equivalent amount of an isotype-matched, control antibody (clone IR418). Supernatants were harvested 48 hours later and assayed as described in Materials and Methods. The results represent the mean of 3 independent cultures (assayed in duplicate) and are representative of 3 independent experiments. The detection limit of the assay was 0.2 pg/mL. Eric Muraille et al. Blood 1999;94:4347-4357 ©1999 by American Society of Hematology

In vivo administration of mγ3-anti CD3ɛ and mitogenic anti-CD3ɛ administration. In vivo administration of mγ3-anti CD3ɛ and mitogenic anti-CD3ɛ administration. (A) BALB/c mice were treated on day 0 with control antibody, mγ3-anti-CD3ɛ, or anti-CD3ɛ (30 μg IV) and analyzed on day 1 for CD3ɛ expression. Pooled spleen cells from 3 individuals in each group were analyzed by immunofluorescence after staining with FITC-labeled anti-CD3ɛ. (B) BALB/c mice (5 per group) were treated with control antibody, mγ3-anti CD3ɛ, or anti-CD3ɛ. Mice were bled 2 hours later and the serum IL-2 activity was tested by ELISA. Results are expressed as the mean absorbance (492 nm) ± SD of individual determinations. Eric Muraille et al. Blood 1999;94:4347-4357 ©1999 by American Society of Hematology

Effect of mγ3-anti CD3ɛ and hamster anti-CD3ɛ administration on allogeneic skin graft survival. Effect of mγ3-anti CD3ɛ and hamster anti-CD3ɛ administration on allogeneic skin graft survival. BALB/c mice were injected with 30 μg of anti-CD3ɛ MoAbs and grafted with MHC-mismatched A/J tail skin on the day of antibody treatment. Control animals were injected with PBS. P < .001 for hamster versus mγ3 anti-CD3ɛ or control, PBS-treated animals; P is not significant for mγ3 anti-CD3ɛ versus control, PBS-treated animals. Eric Muraille et al. Blood 1999;94:4347-4357 ©1999 by American Society of Hematology

Effect of mγ3-anti-CD3ɛ and mitogenic anti-CD3ɛ administration on APC functions. Effect of mγ3-anti-CD3ɛ and mitogenic anti-CD3ɛ administration on APC functions. Spleen cells from control antibody-treated mice, mγ3-anti-CD3ɛ–treated mice, or anti-CD3ɛ–treated mice (50 μg IV) were irradiated and used as accessory cells to stimulate G10-nonadherent responding cells from CBA mice (3 × 105/well). Results are expressed as cpm of [3H] TdR incorporation by responder cells. Eric Muraille et al. Blood 1999;94:4347-4357 ©1999 by American Society of Hematology